31/10/2020
#تحليل دم للكشف الباكر عن الزهايمر متوافر للاستخدام السريري
( المصدر: Medscape
(October 30, 2020
-اصبح التحليل متوافرا" للاستخدام في المخابر بعد سنوات من الدراسة حيث يعمل على قياس مستويات الاميلوئيد بيتا 42 و40 في الدم.
-دقة النتائج تصل الى 86 % ..التحليل حديث وينتظر الحصول على موافقة FDA
The first blood test to detect the presence of amyloid, a hallmark of Alzheimer's disease (AD), is now available for clinical use, the company behind the test's development, C2N Diagnostics, has announced.
How It Works
The physician sends the sample to C2N Diagnostic's specialized laboratory, where it's analyzed using mass spectrometry to measure concentrations of amyloid beta 42 and 40 and to detect the presence of apolipoprotein E isoforms
The company reports that, on the basis of data from 686 patients older than 60 years who had subjective cognitive impairment or dementia, the test correctly identified brain amyloid plaque status, as determined by quantitative amyloid positron-emission tomography (PET) scans, in 86% of the patients. In the analysis, the area under the curve for the receiver operating characteristic was 0.88.
